DFTX (Definium Therapeutics) OCF Yield %: -2.32 (As of Jun. 30, 2026)


DFTX Definium Therapeutics Inc DFTX
32 GF Score
Price $47.04
! 5 Warning Signs
View Full Analysis

What is Definium Therapeutics OCF Yield %?

Definium Therapeutics DFTX +1.07% 32 OCF Yield % is -2.32 as of Jun. 30, 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Definium Therapeutics ranks better than 68.71% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Definium Therapeutics's Trailing 12-Month Cash Flow from Operations is $-144.77 Mil, and Market Cap is $6,244.24 Mil. Therefore, Definium Therapeutics's OCF Yield % for today is -2.32%.

The historical rank and industry rank for Definium Therapeutics's OCF Yield % or its related term are showing as below:

DFTX' s OCF Yield % Range Over the Past 10 Years
Min: -2.35   Med: 0   Max: -2.22
Current: -2.32


During the past 6 years, the highest OCF Yield % of Definium Therapeutics was -2.22%. The lowest was -2.35%. And the median was %.

DFTX's OCF Yield % is ranked better than
68.71% of 1416 companies
in the Biotechnology industry
Industry Median: -8.185 vs DFTX: -2.32

Definium Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Definium Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Definium Therapeutics OCF Yield % Related Terms


Definium Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Definium Therapeutics OCF Yield % Chart

Definium Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -7.88 -60.01 -42.79 -15.14 -9.95

Definium Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.64 -24.07 -13.07 -13.00 -8.67

DFTX vs LGND, XENE, CGON: OCF Yield % Comparison

For the Biotechnology subindustry, Definium Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Definium Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Definium Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Definium Therapeutics's OCF Yield % falls into.


DFTX
32GF Score
Definium Therapeutics Inc DFTX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Definium Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Definium Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-131.56 / 1322.61064
=-9.95%

Definium Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-42.631 * 4 / 1966.4505
=-8.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -2.32 mean?
Definium Therapeutics (DFTX) has a OCF Yield % of -2.32 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Definium Therapeutics and its competitors. According to the industry distribution chart, Definium Therapeutics ranks #443 out of 1416 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Definium Therapeutics' OCF Yield % too high?
Definium Therapeutics' current OCF Yield % is -2.32. Based on the distribution chart, Definium Therapeutics ranks #443 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' OCF Yield % compare to LGND and XENE?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #443 out of 1416 companies for OCF Yield %. This puts Definium Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Definium Therapeutics and its competitors. Definium Therapeutics's current OCF Yield % is -2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current OCF Yield % of -2.32. The current OCF Yield % is -2.32. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current OCF Yield % is -2.32 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Other Exchanges MMQ0:Germany
Address One World Trade Center, Suite 8500, New York, NY, USA, 10007
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score

Get the complete analysis for DFTX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04
Price